




RealRate

PHARMACEUTICAL 2018

Heron Therapeutics INC DE
Rank 229 of 332



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Heron Therapeutics INC DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Heron Therapeutics INC DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 45% points. The greatest weakness of Heron Therapeutics INC DE is the variable Liabilities, Current, reducing the Economic Capital Ratio by 65% points.

The company's Economic Capital Ratio, given in the ranking table, is 190%, being 61% points below the market average of 252%.

Input Variable	Value in 1000 USD
Assets, Current	228,063
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	103,171
Liabilities, Non-Current	0
Other Assets	263
Other Compr. Net Income	7.0
Other Expenses	61,189
Other Liabilities	0
Other Net Income	-2,926
Other Revenues	30,767
Property and Equipment	5,981
Research and Development	138,582
Selling, General and Administrative Expense	25,554

Output Variable	Value in 1000 USD
Assets	234,307
Liabilities	103,171
Expenses	225,325
Revenues	30,767
Stockholders Equity	131,136
Net Income	-197,484
Comprehensive Net Income	-197,480
BaseVar	298,252
ECR before LimitedLiability	52%
Economic Capital Ratio	190%